A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Inclusion Criteria Patients must have: * HIV infection. * Antiretroviral naiveness (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs. * No more than 2 weeks of prior treatment with a protease inhibitor. * No active opportunistic infection or other serious AIDS-defining condition. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Malabsorption or inadequate oral intake. * Lab or clinical abnormality worse than grade 3 (other than exercise-induced CPK elevations). * Unexplained, chronic diarrhea, defined as more than three loose stools per day persisting for 2 weeks or more within the month prior to study entry. * Active malignancy or anticipated need for chemotherapy during the study. * Anticipated need for disallowed medications during the study. Concurrent Medication: Excluded: * Other protease inhibitors. Prior Medication: Excluded: * More than 4 weeks of the prior nucleoside antiretroviral selected for the patient's regimen. * More than 2 weeks of any protease inhibitor.